List of Apellis Pharmaceuticals patents

List of Apellis Pharmaceuticals patents

List of Horiba patents

List of CoAxia patents

List of Custom-Pak, Inc. patents

CEOs of therapy companies

List of companies in iDreamsky Technology's investment portfolio

Patents where

Current Assignee

Name

is

Apellis Pharmaceuticals

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 11040107 Dosing regimens and related compositions and methods	Patent 11040107 was granted and assigned to Apellis Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.		Apellis Pharmaceuticals		United States Patent and Trademark Office	11040107	June 22, 2021
	‌ US Patent 11292815 Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Patent 11292815 was granted and assigned to Apellis Pharmaceuticals on April, 2022 by the United States Patent and Trademark Office.	Apellis Pharmaceuticals	Apellis Pharmaceuticals		United States Patent and Trademark Office	11292815	April 5, 2022
	‌ US Patent 11291407 Detection of high risk drusen	Patent 11291407 was granted and assigned to Apellis Pharmaceuticals on April, 2022 by the United States Patent and Trademark Office.	Apellis Pharmaceuticals	Apellis Pharmaceuticals		United States Patent and Trademark Office	11291407	April 5, 2022
	‌ US Patent 11407789 Cell-penetrating compstatin analogs and uses thereof	Patent 11407789 was granted and assigned to Apellis Pharmaceuticals on August, 2022 by the United States Patent and Trademark Office.	Apellis Pharmaceuticals	Apellis Pharmaceuticals		United States Patent and Trademark Office	11407789	August 9, 2022
	‌ US Patent 11001610 Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof	Patent 11001610 was granted and assigned to Apellis Pharmaceuticals on May, 2021 by the United States Patent and Trademark Office.		Apellis Pharmaceuticals		United States Patent and Trademark Office	11001610	May 11, 2021
	‌ US Patent 10875893 Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods	Patent 10875893 was granted and assigned to Apellis Pharmaceuticals on December, 2020 by the United States Patent and Trademark Office.		Apellis Pharmaceuticals		United States Patent and Trademark Office	10875893	December 29, 2020
	‌ US Patent 11510939 RNAs for complement inhibition	Patent 11510939 was granted and assigned to Apellis Pharmaceuticals on November, 2022 by the United States Patent and Trademark Office.	Apellis Pharmaceuticals	Apellis Pharmaceuticals		United States Patent and Trademark Office	11510939	November 29, 2022
	‌ US Patent 10941184 Cell-penetrating compstatin analogs and uses thereof	Patent 10941184 was granted and assigned to Apellis Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.		Apellis Pharmaceuticals		United States Patent and Trademark Office	10941184	March 9, 2021
	‌ US Patent 11338013 Combination therapy for C3 inhibition	Patent 11338013 was granted and assigned to Apellis Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.		Apellis Pharmaceuticals		United States Patent and Trademark Office	11338013	May 24, 2022
	‌ US Patent 11013782 Methods of treating chronic disorders with complement inhibitors	Patent 11013782 was granted and assigned to Apellis Pharmaceuticals on May, 2021 by the United States Patent and Trademark Office.		Apellis Pharmaceuticals		United States Patent and Trademark Office	11013782	May 25, 2021
	‌ US Patent 10696718 Compstatin analogs for treatment of neuropathic pain			Apellis Pharmaceuticals		United States Patent and Trademark Office	10696718	June 30, 2020
	‌ US Patent 11903994 Dosing regimens	Patent 11903994 was granted and assigned to Apellis Pharmaceuticals on February, 2024 by the United States Patent and Trademark Office.	Apellis Pharmaceuticals	Apellis Pharmaceuticals		United States Patent and Trademark Office	11903994	February 20, 2024
	‌ US Patent 11712460 Methods of treating chronic disorders with complement inhibitors		Apellis Pharmaceuticals	Apellis Pharmaceuticals		United States Patent and Trademark Office	11712460	August 1, 2023
	‌ US Patent 11661441 Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof		Apellis Pharmaceuticals	Apellis Pharmaceuticals		United States Patent and Trademark Office	11661441	May 30, 2023

14 results

0 selected

14 results

0 selected